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ABSTRACT
Enhancer regions and transcription start sites of
estrogen-target regulated genes are connected by
means of Estrogen Receptor long-range chromatin
interactions. Yet, the complete molecular mecha-
nisms controlling the transcriptional output of en-
gaged enhancers and subsequent activation of cod-
ing genes remain elusive. Here, we report that CTCF
binding to enhancer RNAs is enriched when breast
cancer cells are stimulated with estrogen. CTCF bind-
ing to enhancer regions results in modulation of
estrogen-induced gene transcription by preventing
Estrogen Receptor chromatin binding and by hinder-
ing the formation of additional enhancer-promoter
ER looping. Furthermore, the depletion of CTCF fa-
cilitates the expression of target genes associated
with cell division and increases the rate of breast
cancer cell proliferation. We have also uncovered a
genomic network connecting loci enriched in cell cy-
cle regulator genes to nuclear lamina that mediates
the CTCF function. The nuclear lamina and chromatin
interactions are regulated by estrogen-ER. We have
observed that the chromatin loops formed when cells
are treated with estrogen establish contacts with the
nuclear lamina. Once there, the portion of CTCF as-
sociated with the nuclear lamina interacts with en-
hancer regions, limiting the formation of ER loops
and the induction of genes present in the loop. Col-
lectively, our results reveal an important, unantici-
pated interplay between CTCF and nuclear lamina to
control the transcription of ER target genes, which
has great implications in the rate of growth of breast
cancer cells.
INTRODUCTION
Estrogen-induced gene transcription is regulated by cis-
regulatory regions containing sets of DNA-binding pro-
teins (1). The interaction of these proteins with DNA is
time-specific and usually is orchestrated by estrogen. More-
over, these regulatory regions are located hundreds of kilo-
bases away from transcription start sites (TSS) of the target
gene (2). Cohesin and condensin have recently been shown
to positively regulate transcription by modulating enhancer
function and enhancer–promoter looping (3,4). Yet, the role
of other architectural proteins involved in nuclear organiza-
tion, such as the transcriptional regulator CCCTC-binding
factor (CTCF), is unexplored. CTCF is an ubiquitous mul-
tivalent zinc finger protein that regulates higher-order chro-
matin organization (5). A large number of studies have fo-
cused on the mechanism underlying the different functions
achieved by CTCF in genome biology. Most of the research
supports the idea that CTCF is able to participate in insu-
lation and various aspects of transcriptional regulation by
mediating long-range interactions between two or more ge-
nomic loci. Other functions such as RNA pausing regula-
tion and alternative splicing have also have been proposed
(6,7). Interestingly, CTCF is frequently altered in ER pos-
itive breast cancers (8,9). Yet, the molecular role of CTCF
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in the regulation of estrogen-induced transcription and the
consequences of its alterations are poorly understood.
Previous advances in sequencing technology have facili-
tated the genome-wide identification of regulatory elements
based on chromatin accessibility, posttranslational histone
modifications and the binding of regulatory factors. More
recently, the incorporation of novel methodologies such as
global run-on sequencing (GRO-seq) has allowed mapping
of the position and the orientation of transcriptionally en-
hancer RNAs (eRNAs) at genome-wide level (1). These eR-
NAs are likely to have important functions in many reg-
ulated programs of gene transcription (10). Furthermore,
the identification of estrogen induced eRNAs has aided the
study of mechanisms underlying estrogen-ER regulation of
breast cancer gene expression (1).
In this study, we focused on the role of the chromatin-
binding protein CTCF in orchestrating estrogen-specific
gene transcription. We observed that CTCF performs as
a transcriptional repressor by interacting to chromatin re-
gions of eRNAs and promoter to control transcriptional
regulation induced by estrogen. CTCF regulates target gene
expression by hindering the ER binding and the forma-
tion of ER chromatin loops induced by estrogen, thereby
modulating a subset of estrogen-specific gene transcripts.
Remarkably, the repressive function of CTCF is associated
with its ability to impede the proliferation mediated by ER.
Finally, our data showed that CTCF binding to eRNAs and
promoters is facilitated by estrogen when chromatin estab-
lishes contacts with nuclear lamina.
MATERIALS AND METHODS
Cell culture
MCF-7 cells were obtained from American Type Culture
Collection (ATCC, Manassas, VA, USA). Cells were grown
in Dulbecco’s modified Eagle’s medium (DMEM), supple-
mented with 10% fetal bovine serum.
Chromatin Immunoprecipitation (ChIP)
CTCF, ER and LaminB genomic regions were identified by
using the cross-linking (X)-ChIP protocol as described pre-
viously (11). MCF-7 cells were grown in hormone-stripped
media with 5% of charcoal-stripped serum and treated with
vehicle (control) or estrogen for 0 h, 45min or 3 h. Cells were
fixed with 1% formaldehyde for 10 min and then quenched
with 125 mM of glycine. Cells pellets were washed with
phosphate buffered saline (PBS) and lysed with lysis buffer.
DNA fragmentation was done by using Bioruptor sonica-
tor (Diagenode) (17–20 cycles on and off 30 s).We inspected
the fragmentation size of DNA after sonication tested res-
olution of the ChIP-Seq. Fragment length was typically
200–500 bp, visualized on a 1.5% agarose gel. Chromatin
was incubated overnight at 4◦C with 5 g specific anti-
bodies CTCF (Millipore 07–729; Lot: 2453497), ER (Santa
Cruz sc543; Lot: F1215), FOXA1 (Abcam ab5089; lot
GK122110-17, FOXA1 ab23738; lotGR176970-1), LaminB
(Santa Cruzc-20; sc-6216; Lot F1715) and equal amounts
of Protein A&G Dynal Beads (Life technologies). Western
blot was performed visualizing specific bands of each anti-
body used for the ChIP-Seq (Additional file 1). The beads
were washed and DNA was eluted by reverse crosslink
overnight at 65◦C. For the Re-ChIP similar protocol was
used, however, after the first IP DNA was eluted in 100 l
Re-ChIP elution buffer (10 mM DTT 1% SDS) and incu-
bated 30 min at 37◦ with shaking. The elution was removed
from the beads and diluted 1:70 in dilution buffer (1% Tri-
ton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl
pH 8.0) before the second immunoprecipation (IP) was per-
formed as a standard ChIP procedure.
The libraries for next-generation DNA sequencing
(NGS) were made with Illumina TruSeq ChIP Sample
Preparation Kit (IP-202-1012) where DNA of desired size
was cut from gel after specific indexes had been added or
Diagenode MicroPlex Library Preparation kit (C05010010
(AB-004-0012)). Each sample was run on bioanalyser be-
fore submission to NGS.
Transfection
Cells were seeded in 6 well plate to be 50% confluent upon
transfection. Cells were transfected with siRNA targeting
CTCF (ON-TARGET J-010319-05-0005, Thermo Fisher
Scientific) and siControl Non-targeting (siNT) (AllStars,
Qiagen) using Lipfectamine RNAiMax (Life technologies)
to a final concentration of 40 nM.
ChIP sequencing data analyses
ChIP DNA was amplified as previously described (11).
Reads generated by the genome analyzer were aligned
against the human genome using Bowtie 2 software (http:
//bowtie-bio.sourceforge.net/bowtie2/index.shtml) with de-
fault parameters. Samtools was used to convert the SAM
file into BAM and subsequently sort the BAM file. Dupli-
cate reads were removed with samtools and the resulting file
was converted into a BEDfile containing the aligned unique
reads. Peaks were called withMACS2 with default parame-
ters (P-value < 0.01) or MACS2 1.4.2 (P-value < 1e-4) was
used to call the peaks over the MCF7 input DNA.
Moreover, sequencing data, CTCF and ER binding sites
are available with GSE8510 accession number.
To determine the number of ER loops that presented
CTCF signal, we considered all the ER start sites involved in
loop formation and we measured the signal of CTCF (nor-
malized by signal input) in a window of 10 Kb from the
center of the ER start site. We considered ER loops with
CTCF binding when in CTCF signal was positive (higher
than 0). For the analysis, we considered only ER loops with
a minimal distance of 20 Kb from the ER start to the ER
end sites (2151 ER loops).
Real-time PCR
DNA eluted from ChIP, from 3C experiments and from
cDNA were analyzed by real-time PCR (RT-PCR) using
SYBR Green and specific primers. All the selected primers
had annealing temperature 60◦ and are listed in the Sup-
plementary Table S1. Primer-specific PCR mix were ob-
tained by diluting Power SYBRGreen MasterMix (Applied
Biosystems, cat. 4367659) 1:1 and primers to a final con-
centration of 100 nM. Typically, 2 l of ChIP or 3C eluted
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DNA and of 1:100 cDNA dilution (1 g of RNA retro-
transcribed) were added to each well. For each experiment,
samples were run in triplicates on MicroAmp plates (cat.
4346906, Applied Biosystems) for 40 reaction cycles in Ap-
plied Biosystem 7900 HT Fast RT-PCR System. The curves
obtained were quantified with the software SDS 2.4 (Ap-
plied Biosystems). Inverse logarithms of ChIP Ct values
were normalized on DNA content and on input from non-
ChIPpedmaterial. For 3C experiments, 3C values were nor-
malized over unligated samples and on DNA content. For
expression analysis, gene-specific values were normalized
over UBC control for each condition. A MIQE checklist
table with details for RT-PCR is included in the Supplemen-
tary Data (Supplementary Table S2).
Motif analyses
To assess the presence of binding motifs of in the CTCF
bound regions, we looked for overrepresented motifs using
‘findMotifsGenome.pl’ part of the HOMER package (v4.7)
(12).
RNA isolation, quality control and RNA-seq analysis. Af-
ter siCTCF transfection, cells were isolated and the culture
medium was removed after the centrifugation of the cell
suspension. Total RNA was isolated with the total RNA
isolation kit according to the manufacturer’s protocol (Qi-
agen RNeasy kit). RNA yield was assessed spectrophoto-
metrically (NanoDrop 2000). Total RNA was isolated with
the total RNA isolation kit (RNeasy, Qiagen) according to
the manufacturer’s protocol. RNA yield was assessed spec-
trophotometrically (NanoDrop 2000). A total of 500 ng of
RNA were used for cDNA transcription with SuperScript
III (Life technologies) and random primers. cDNA was an-
alyzed by RT-PCR with gene-specific primers and SYBR
Green. Quantification and quality control for RNA-seq li-
braries were performed by Agilent Bioanalyzer (RNA nano
6000, Agilent). RNA libraries for RNA-seq were prepared
according to Illumina protocol and paired-end sequencing
was performed at Norwegian Sequencing Centre.
The paired-end RNAseq data were aligned by using
tophat. The gene expression values (FPKM) were calcu-
lated by using cufflinks. The differential expression values
and plots were generated by using Cuffmerge and Cum-
meRbund. RNA sequencing is available withGSE85108 ac-
cession number.
GRO-seq analysis
TheGRO-seq data for respective time points (0min , 40min
and 150min) were downloaded fromHah et al. (1).With the
help of liftover tool we converted the genomic coordinates
from Hg18 to Hg19. For this analysis, first we categorized
CTCF binding sites in to three different categories based on
their genomic location: Promoter (±5 kb gene start), gene
body (gene start +5 kb to gene end, including 3′) and rest
as intergenic. The percentage ofGRO-seq reads overlapping
with genomic distribution (promoter, gene body, intergenic)
of CTCF binding sites were calculated for respective time
points. The R and python scripts used in the analysis are
available at bit bucket (https://bitbucket.org/yogita sharma/
ctcf).
Metacore pathway analysis
Significantly differentially regulated identified genes were
uploaded toMetaCore fromGeneGo Inc for process (www.
genego.com), network and pathway map analysis.
Cell proliferation assay
Cells were seeded at equal confluence and the effect of
CTCF depletion on cell proliferation were measured by live
cell imaging Incucyte (Essen BioScience).
Chromatin fractionation
MCF-7 cells were grown in the same manner as described
in the previous sections. The medium was removed and
the cells were scraped in cold PBS containing proteinase
and phosphatase inhibitors (Thermo Scientific) and sub-
sequently pelleted by centrifugation. Each cell pellet was
incubated for 10 min in 200 l of cold buffer A (10 mM
Hepes [pH 7.9], 10 mM KCl, 1.5 mM MgCl2, 0.34 M su-
crose, 10% glycerol, 1 mM DTT, protease and phosphatase
inhibitors (Thermo Scientific) supplemented with 0,1% Tri-
ton X-100. The samples were subjected to low-speed cen-
trifugation (4 min, 1300 g, 4◦C) to collect the nuclei, which
were subsequently washed in 200 l of buffer A. The pel-
leted nuclei were lysed in 200 l of buffer B (3 mM EDTA,
0.2 mM EGTA, 1 mM DTT, protease and phosphatase in-
hibitors (Thermo Scientific)) and kept on ice 30 min. After
three washes in buffer B, the chromatin pellets were resus-
pended in 200 l of buffer B and sonicated for 30 s (Biorup-
tor, Diagenode) to shear DNA. Chromatin was pelleted by
centrifugation (5 min, 16 000 g, 4◦C), and the pellets were
resuspended in buffer B supplemented with 4x loading dye
(Life Technologies GmbH).
Western blots and IP
Cells were lysed (50 mM Tris-HCl, pH7.4; 100 mM NaCl;
1 mM EDTA; 1 mM EGTA; 1 mM NaF; 0.1% SDS;
0.5% Sodium Deoxycholate; 1% Triton-X-100; 2 mM
SodiumOrthovanadate; Protease Inhibitor Cocktail (Ther-
mofisher)). Protein levels were quantified by BSA assay
(BSA Assay, Thermo fisher). Protein lysate was resolved
using precast SDS-PAGE gels, and transferred to PVDF
membrane. Blots were blocked and incubated overnight at
4◦C with primary antibodies. Blots were incubated with
an HRP-conjugated secondary antibody and developed us-
ing ECL Western blotting substrate. Antibodies used were:
ER (sc-543) from Santa Cruz Biotechnologies, -Actin
(4970S) from Cell signaling, CTCF (07-729 Millipore) and
histone H3 (ab1791) from Abcam.
Mass spectrometry and data analysis
Proteins were dissolved in 50 l 6 M urea and 100 mM am-
monium bicarbonate, pH 7.8. For reduction and alkylation
of cysteines, 2.5 l of 200 mM DTT in 100 mM Tris-HCl,
pH 8 was added and the samples were incubated at 37◦C for
1 h followed by addition of 7.5 l 200 mM iodoacetamide
for 1 h at room temperature in the dark. The alkylation
reaction was quenched by adding 10 l 200 mM DTT at
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37◦C for 1 h. Subsequently, the proteins were digested with
2 g trypsin for 16 h at 37◦C. The digestion was stopped
by adding 5 l 50% formic acid and the generated pep-
tides were purified using a Strata C18-E SPE column (Phe-
nomenex, Værløse, Denmark), and dried using a Speed Vac
concentrator (Savant, Holbrook,NY,USA). The dried pep-
tides were dissolved in 10l of aqueous 2% acetonitrile con-
taining 1% formic acid. Five microliters of sample was in-
jected into a Dionex Ultimate 3000 nano-UHPLC system
(Sunnyvale, CA, USA) coupled online to an LTQ-Orbitrap
XL mass spectrometer (ThermoScientific, Bremen, Ger-
many) equipped with a nano electrospray ion source. For
liquid chromatography, aqueous 2% acetonitrile containing
0.1% formic acid was used a solvent A and solvent B con-
tained 0.1% formic acid in 90% acetonitrile. Peptides were
separated on an Acclaim PepMap 100 column (C18, 3 m
particle diameter, 100 A˚ pore size, 75 m internal diameter,
50 cm length) at a flow rate of 0.3 l/min using solvent gra-
dients of 7% B to 35% B in 40 min, to 35% B to 50% B (3
min) and finally to 80% B in 2 min. An ion spray voltage of
1.7 kV, tube lens voltage of 120V and transfer capillary tem-
perature of 200◦C were used. The mass spectrometer was
operated in data-dependent acquisition mode and precur-
sor ion survey scans (400 m/z to 2000 m/z) were acquired
in the orbitrap analyzer with resolution R = 60 000 at 400
m/z (after accumulation to a target of 500 000 charges in the
LTQ). The fragmentation spectra were acquired in the lin-
ear ion trap using collision induced dissociation at a target
value of 10 000 charges (normalized collision energy 35%,
activation time 30 ms, activation Q 0.25, isolation width 2)
for the top seven most abundant ions with a dynamic exclu-
sion time of 60 s.
The raw data were searched against the SwissProt hu-
man database (11/2013, 20 279 entries) usingMascot search
engine (Matrix Science, London, UK, version: 2.4.0). The
following search parameters were used: enzyme: trypsin,
maximum missed cleavage sites: 1, precursor ion mass tol-
erance: 10 ppm, fragment ion tolerance: 0.6 Da, variable
modifications: oxidation on methionine and acetylation at
N-terminus. Peptide and protein identifications were fur-
ther validated with Scaffold (version 4.4.4, Proteome Soft-
ware Inc, Portland, OR, USA). Peptide identifications were
accepted if they could be established at greater than 95%
probability by the Peptide Prophet algorithm with Scaffold
delta-mass correction. Protein identifications were accepted
if they could be established at greater than 99% probability
and contained at least two identified peptides. The Protein
Prophet algorithm assigned protein probabilities.
Chromosome Conformation Capture (3C)
Job Dekker’s protocol was followed with minor modifica-
tions (13). For each condition, one 15 cm dish of MCF-7
cells was transfected with siNT and siCTCF. After 72 h of
hormone depletion, when they reached 70–80% confluence,
cells were treated with Estrogen 100 nM for 0 h, 45 min or 3
h and crosslinked for 10 min in DMEM 1% formaldehyde.
After quenching with glycine 125 mM, cells were scraped as
previously described and each cell pellet was resuspended in
5ml of lysis buffer (10mMTris-HCl pH7.5, 10mMNaCl, 5
mMMgCl2, 0.1mMEGTA,Complete proteinase inhibitor
Roche). Nuclei were isolated by centrifugation at 500 g for
5 min and subsequently incubated for 1 h at 37◦ in 0.5 ml
of 1.2x restriction enzyme buffer with 0.3% SDS. Triton-X-
100 was added to the samples at a final concentration of 2%
and samples were incubated for one more hour at 37◦. After
this, each sample was digested overnight with 400 U of the
specific restriction enzyme (BglII for P2RY2 region, New
England Biolabs). After restriction enzyme inactivation at
65◦, the digested nuclei were resuspended in 7 ml of ligation
buffer supplemented with 1% triton-X-100. After 1-h incu-
bation at 37◦, 800 U of T4 ligase (New England Biolabs)
were added to each sample and samples were ligated for 4
h at 16◦ followed by 30 min at room temperature. Samples
were reverse crosslinked and proteins were digested by Pro-
teinase K (Life Technologies) overnight at 65◦. After RNA
digestion by RNAse A (Life Technologies), DNA was iso-
lated by Phenol Chloroform extraction followed by Ethanol
precipitation. DNA was quantified by Qubit and analyzed
by RT-PCR Syber Green using primers specific for each ge-
nomic region.
RESULTS
Estrogen influences CTCF chromatin interactions in a time
specific fashion
In order to determine whether estrogen might influence
CTCF chromatin interactions we performed CTCF ChIP-
sequencing in breast cancer cells responsive to Estrogen
(MCF-7) upon different stimulation time points (0 h, 45
min and 3 h). CTCF chromatin binding sites were called
using MACS (14) by considering unique sequencing reads.
Differences in CTCF chromatin-binding regions were iden-
tified in cells treated with estrogen (18,302 in 45 min and
19,901 in 3 h) compared to non-treated cells (23,168 in 0 h)
(Figure 1A; Additional file 2A). The comparison of CTCF
binding between treated and non-treated cells revealed that
estrogen influences CTCF by facilitating time-specific chro-
matin interactions (Figure 1B–D). In order to characterize
time-specific CTCF interacting proteins, we performed de
novo motif analysis of the regions bound by CTCF upon
time-specific estrogen stimulations. We found a significant
enrichment of CTCF and BORIS motifs at 45 min, whilst
FOXA1 and GATA3 motifs were enriched at CTCF bound
regions induced at 3 h (Figure 1E). The chromatin immuno-
precipitation of FOXA1 followed by CTCF confirmed that
FOXA1 mediates the CTCF chromatin interaction at 3 h
of estrogen stimulation (Additional file 2B). All together,
these results suggested that estrogen regulated CTCF bind-
ing occurs by direct contacts with chromatin or through
ER-associated proteins such FOXA1.
Next, we determined the distribution of estrogen-
regulated CTCF chromatin interactions at genome-wide
level. To facilitate this analysis we first classified CTCF
binding sites according to their distance from annotated
gene transcripts (i.e. those at promoter, gene body and in-
tergenic). We observed that around 50% of the binding
sites were localized at intergenic regions (Figure 2A). To
get a better understanding of the mechanism of estrogen-
influenced CTCF binding, we compared global run-on ex-
periment followed by High throughput sequencing (GRO-
seq) from MCF7 cells stimulated with estrogen at differ-
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Figure 1. Estrogen influences CTCF chromatin binding interactions. (A) ChIP-sequencing of CTCF in MCF-7 cells treated with vehicle (0 h) or estrogen
for 45 min or 3 h. (B) Overlap of CTCF binding events among different time of estrogen treatment. (C) Heatmap showing the signal intensity of CTCF
chromatin regions with preferred binding at 0 h, 45 min and 3 h of estrogen stimulation. The heatmap of the overlapping regions is also shown. (D)
Boxplots showing changes in CTCF signals for sites identified with estrogen treatment. (E) Top-enriched transcription factor motifs identified by de novo
motif discovery at CTCF preferred binding at 0 h, 45 min or 3 h of estrogen stimulation.
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Figure 2. Estrogen-regulated CTCF binding correlates with estrogen-regulated gene transcripts and enhancer RNAs. Relative overlap of CTCFwithin (A)
the total of transcripts (defined from UCSD genes) or (B) estrogen regulated transcripts (defined from GRO-seq (10)). The genomic regions were defined
as: gene promoter (defined as ±5 kilobases from gene start), gene body (defined from +5 kilobases from gene start to gene end) and intergenic regions
(defined from −5 kilobases from gene start to gene end).
ent time points. For that analysis we retrieved an existing
GRO-seq data set in MCF-7 cells stimulated with estrogen
for different time points (1). Then, we analyzed the bind-
ing of CTCF at eRNAs, promoter and gene transcript de-
tected from GRO-seq analyses. We found that around 30%
of CTCF binding sites overlapped with estrogen-induced
transcripts in any of the genomic regions analyzed (data not
shown). We focused on these overlapping regions and we
observed a higher enrichment for CTCF binding at 45 min
of estrogen stimulation to the promoter regions of early es-
trogen up-regulated genes (25.4%; Figure 2B) compared to
non-estrogen regulated genes (12.5%; Figure 2A). We also
detected enrichment of CTCF binding to the promoter of
estrogen down-regulated genes or up-regulated at later time
points (Figure 2AandB). Finally, we also observed a gain of
CTCF binding at gene bodies of genes that were regulated
at both early and late time points, although this enrichment
was less clear than that for the early-regulated set of genes
(Figure 2A and B).
Next, we quantified the CTCF binding intensity at the
overlapping regions with estrogen regulated eRNAs, pro-
moter regions and gene transcripts across the different time
points. The analysis showed a positive correlation between
CTCF signal upon 0 h and 45 min of estrogen stimulation
at both eRNAs and promoters/gene bodies of estrogen-
induced genes and their expression at the same time points
(Figure 3A). Interestingly, a significant increase of CTCF
binding was detected at 45 min of estrogen stimulation at
all the GRO-seq regions analyzed (Figure 3A). Consistent
with these findings, we also observed that the gain of CTCF
binding at 3 h resulted in reciprocal increase in estrogen-
dependent transcription at a similar time point (Figure 3B).
Finally, we could identify a similar correlation for estrogen
down-regulated transcripts with CTCF binding sites at 0 h
(Figure 3C).
To better understand how CTCF chromatin interactions
may relate to estrogen receptor (ER) function, we analyzed
the binding of ER in MCF-7 cells stimulated with estrogen
at different time points (0 h, 45 min and 3 h) in GRO-seq re-
gions containing CTCF binding and compared with GRO-
seq regions without CTCF binding. Previously, we reported
that FOXA1 is a transcription factor determinant for ER
functionality (15). Hence, we also examined the binding
of FOXA1 at these GRO-seq regions (i.e. with or with-
out CTCF binding). Upon estrogen treatment for 45 min,
we observed an increase of ER binding at both GRO-seq
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Figure 3. Time specific estrogen-induced CTCF binding correlates positively with time specific estrogen-induced transcripts. Box plots showing changes
in CTCF signals from genomic regions as defined in Fig. 2 of (A) early estrogen-induced transcripts (40 min), (B) late estrogen-induced transcripts (150
min) or (C) estrogen-repressed transcripts (0 h).
regions. However, ER binding was significantly increased
at GRO-seq non-overlapping with CTCF. Interestingly, the
binding of FOXA1 was significantly reduced CTCF and
GRO-seq overlapping regions when cells were stimulated
with estrogen at 45 min, whereas it was significantly in-
creased at GRO-seq non-CTCF overlapping (Additional
file 3A). Then, we investigated the enrichment of histone
mark associated with active transcription (H3K4me1 and
H3K36me3) at these GRO-seq genomic regions (i.e. with or
without CTCF binding)(Additional file 3B). The binding of
CTCF correlated negatively with the levels of histone mod-
ifications at GRO-seq and CTCF overlapping regions. By
contrast, we detected a positive correlation for non-CTCF
regions. All together, these results suggested that CTCF
binding induced by 45 min of estrogen stimulation to chro-
matin regions associated with repression and that CTCF
might play an important role in the control of estrogen-
induced gene transcription.
CTCF binding prevents ER chromatin interaction and loop
formation
Previously, Hah et al. reported that about 50% of ER bind-
ing regions were in fact overlapping with eRNAs identified
at intergenic regions (1). Interestingly, our results suggest
that ER binding is significantly reduced at GRO-seq (in-
cluding eRNAs) sites where CTCF binds. To investigate the
effect of CTCF on ER binding to chromatin, we transfected
MCF-7 cells with control small inhibitory RNA (siControl)
or a siRNA against CTCF (siCTCF). After transfection,
cells were hormone-deprived and consequently treated or
non-treated with estrogen for 45 min. Subsequently, protein
from the chromatin fraction was blotted against ER. The
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global binding of ER to chromatin was increased in CTCF
depleted cells, while CTCF depletion did not make any sig-
nificant effect on ER protein expression (Figure 4A and B).
We validated this finding by silencing CTCF and analyz-
ing the ER chromatin interaction by ChIP-sequencing (Fig-
ure 4C). Our results revealed that CTCF depletion resulted
in a gain of 24% of novel ER binding regions, whereas al-
most all the ER interactions identified in CTCF expressing
cells were still conserved (Figure 4C). The genomic distri-
bution of these novel ER sites revealed a gain at promoter
and introns compared to non-CTCF affected ER binding
sites (Figure 4D).
ER plays an important role in the establishment of intra-
chromosomal interactions. In fact, ER chromatin loops
induced by estrogen at 45 min correlate positively with
estrogen-dependent target gene activation (16). To find out
whether CTCF could be involved in estrogen-induced ER
loops, we retrieved an existing ER ChIA-PET data set (16),
which maps all the ER–ER chromatin loops induced by es-
trogen at 45 min. We assayed for the ER loops induced by
estrogen and analyzed the fraction of ER loops contain-
ing CTCF binding. We mapped ER and CTCF binding in
MCF-7 cells non-treated or treated with estrogen at 45 min
and 3 h. The analysis showed that around 52% of the ER
chromatin loops were associated with CTCF binding (Fig-
ure 5A, Additional file 4A). CTCF binding was detected
around the estrogen-ER induced loops at 45 min. Interest-
ingly, similar to ER,CTCFbinding correlatedwith estrogen
treatment, which suggested a positive correlation between
CTCF and ER binding to chromatin (Figure 5A). There-
fore, we hypothesized that CTCF could influence ER loop
formation. To test the hypothesis, we investigated the effect
of CTCF depletion on ER binding and ER-loop forma-
tion on the estrogen-induced gene P2RY2, which has been
previously well characterized (16). A representative genome
browser image of aforementionedChIP-seq results is shown
for P2RY2 locus (Figure 5A). Two ER–ER loops have been
described to establish contact with P2RY2 gene: ER loop
between ER site 1 and ER site2 (∼37 Kb) and ER loop be-
tween ER site 1 and ER site 3 (∼400 Kb). The CTCF map
at this genomic region reveal the presence of at least two
CTCF sites enriched with estrogen at 45 min, which were
flanking the ER site 3. CTCF regions nearby ER sites 1 and
2 were also identified but these CTCF sites were not flank-
ing ER binding sites. To appreciate the effect of CTCF de-
pletion, we transfected MCF-7 cells with Control or CTCF
targeting siRNA and stimulated with estrogen for 45 min.
Next, we tested ER binding and ER–ER loop formation
at the previously characterized sites. Chromosome confor-
mation capture (3C)-PCR showed that ER site1-ER site 3
chromatin loop was significantly induced in CTCF depleted
MCF-7 cells. On the contrary, the interactions between ER
site1 andER site 2 and a negative control regionwere not in-
fluenced (Figure 5C). Interestingly, an increase of ER bind-
ing at the ER looping site 3 was also observed upon CTCF
silencing (Additional file 4B), suggesting that CTCF hin-
ders the formation of precise ER–ER loops by reducing ER
chromatin binding. Hence, these results indicate that CTCF
limits gene loop formation and possibly the transcription of
these genes.
CTCF modulates transcription of cell cycle associated genes
and buffers cell growth
We hypothesized that CTCF recruitment to ER-regulated
genomic regions upon estrogen treatment might reflect a
buffering mechanism to dampen the expression of target
genes. To confirm this hypothesis we assessed the effects
of CTCF depletion on global estrogen regulated gene tran-
scription. We transfected hormone-deprived MCF-7 cells
with siControl or siCTCF and treated them with vehicle
or estrogen. We performed RNA-sequencing (RNA-seq)
and examined the impact of CTCF on estrogen-regulated
genes. Strikingly, our analysis showed that around 32%
of estrogen-induced gene transcripts were influenced by
CTCF depletion. The major fraction of these transcripts
was down regulated by at least 1.5-fold change, whereas
the other smaller fraction of genes was up regulated (Fig-
ure 6A and B; Additional file 5A and B). These results
suggested that CTCF represses the expression of a sub-
stantial number of estrogen-induced genes. We validated
these findings by increasing CTCF protein in MCF-7 cells
and determining the expression by RT-PCR of a subset of
estrogen-induced genes that we identified to be up regulated
in CTCF depleted cells. The overexpression of CTCF in-
hibited the transcription in all the genes tested (Additional
file 6A and B). To determine the functional significance of
CTCF regulated-gene transcription, we performed Meta-
core Pathway analysis of CTCF-regulated estrogen-induced
genes. The top significant pathways associated with CTCF
down regulated-genes included G1/S checkpoint and cell
cycle regulation of G1/S transition (Figure 6C; Additional
file 6C). Furthermore, CTCF silencing resulted in a signif-
icant increase of cell proliferation mediated by ER (Fig-
ure 6D)(P < 0.03). All together, these findings suggested
that the primary function of CTCF in the control of ER-
mediated proliferation is tomodulate the expression of gene
transcripts key for cell division.
Nuclear Lamina mediates CTCF repressive function
Next, we investigated the mechanism by which CTCF in-
teracts with the chromatin upon estrogen treatment. We
used proteomic approaches to identify regulatory targets
of CTCF specific for breast cancer cells. For that, we per-
formed CTCF immunoprecipitation of chromatin enriched
protein fraction coupled with mass spectrometry as previ-
ously described (17) by means of Rapid Immunoprecipita-
tion of Endogenous proteins method (RIME). This method
uses formaldehyde cross-linked cell extracts, which main-
tain transient protein-protein interactions. Then, CTCF
protein is immunoprecipitated and pulled down proteins
are identified by mass spectrophotometry. We performed
CTCFRIME inMCF-7 cells hormone depleted and treated
with vehicle (0 h) or estrogen (45 min and 3 h) (Figure
7A). Proteins associated with nuclear lamina were identi-
fied among the CTCF–binding targets (Figure 7B). These
partners were validated byCTCF immunoprecipitation and
Western blot (Additional file 7A). Previously, nuclear lam-
ina has been linked to transcription regulation by orga-
nizing chromatin into active and inactive domains (18,19).
Moreover, nuclear lamina is known to interact with CTCF
to tether chromatin regions into sub-nuclear periphery to
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Figure 4. CTCF constrains global ER chromatin binding and ER chromatin looping. (A) MCF-7 cells were transfected with siControl or siCTCF, treated
with vehicle (0 h) or estrogen for 45 min (E2) and were fractionated to enrich the chromatin fraction, which was protein blotted with CTCF and ER
antibodies. Histone H3 was used as a control. (B) ER levels were tested from protein extracts of MCF-7 cells transfected with siControl or siCTCF, treated
with vehicle (0 h) or estrogen for 45 min (E2). Actin was used as a loading control. (C) Overlap of ER binding events induced by estrogen (45 min) and
analyzed by ChIP-sequencing of ER in MCF-7 cells transfected with siNT or siCTCF. (D) Genomic distribution of ER consensus or ER induced sites.
modulate transcription (20). To get insight into the role of
nuclear lamina in the control of CTCF binding to the chro-
matin, we characterized the Lamin B genomic interactions
within the defined ER–ER chromatin loops associated with
CTCF binding. For that, we mapped Lamin B interaction
to the chromatin by ChIP-seq in MCF-7 cells treated with
estrogen at 0 h, 45 min and 3 h. Then, we quantified Lamin
B interaction within ER-chromatin loops containing CTCF
binding (Additional file 7B). This analysis showed that the
nuclear lamina established contacts with the ER chromatin
loops in cells stimulated with estrogen for 45 min. Interest-
ingly, we found a positive correlation between nuclear lam-
ina and CTCF binding at these chromatin interaction. To
appreciate the role of CTCF in nuclear lamina contacts with
ER chromatin loops, we tested Lamin B chromatin interac-
tions at the ER sites involved in the loop formation around
P2RY2 gene upon CTCF silencing. We observed that ER
site 1 and 3 were associated with nuclear lamina when cells
were stimulated with estrogen at 45 min (Figure 7C). The
depletion of CTCF resulted in the loss of contact between
nuclear lamina and the ER binding site 3, which is a ER
distal site involved in the formation of looping between ER
site1 and ER site 3. On the contrary, the contact between
nuclear lamina and the ER binding site 1 was unaffected
(Figure 7D). These results, together with the finding that
ER-chromatin looping between ER sites 1 and 3 was fa-
cilitated in CTCF depleted cells (Figure 5c), indicate that
the positioning of ER loops to the nuclear lamina might be
a mechanism by which CTCF might control the transcrip-
tion of ER target genes. Interestingly, our results also show
that ER site 2 is not associated with nuclear lamina (Fig-
ure 7C), which supports the hypothesis that the formation
of ER loop between site 1 and 2 is not impeded by CTCF.
All together, our data suggest that following the
chromatin–nuclear lamina contact, CTCF associated with
nuclear lamina binds to selective genomic regions around
estrogen-induced genes as a mechanism to hinder the for-
mation of additional ER loops and thereforemodulate gene
transcription. By contrast, inCTCFdepleted cells, the bind-
ing of ER to chromatin andER chromatin loop is facilitated
and consequently gene transcription and cell growth is am-
plified (Figure 7E).
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Figure 5. Estrogen-induced CTCF binding with chromatin at 45 min influences ER chromatin loop assembly. (A) Average signal intensity of ER and
CTCF binding events of ER chromatin loops with CTCF overlapping binding regions. (B) CTCF binding intensity in non-stimulated cells (0 h, blue) or
stimulated with estrogen (45 min, red) is plotted at ER sites 1 and 2 involved in ER looping formation of P2RY2 gene. RNA polymerase II binding intensity
in stimulated cells with estrogen (45 min, green) is plotted at ER site 1. (C) MCF-7 cells were transfected with siControl or siCTCF, treated with vehicle
(0 h) or estrogen for 45 min (E2) and ER ChIP and 3C was performed followed by RT-PCR of ER binding events already identified to be involved in ER
loop formation for P2RY2 gene. The data are the mean of three independent replicates ± s.d.
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Figure 6. CTCF modulates the expression of a subset of estrogen-induced genes. (A) MCF-7 cells were transfected with siControl or siCTCF, treated
with estrogen and RNA was sequenced. We used 1318 estrogen-induced genes at 40 min and published previously (1) to calculate expression levels for
each gene induced by estrogen in cells depleted or expressing CTCF (RKPM). Then we measured the fold change (FC) expression (siCTCF/siNT) and
determined the fraction of genes with an 1.5 FC increase or decrease. (B) Box plot of normalized RNA levels of CTCF regulated genes (with at least 1.5
FC) or non-regulated genes. (C) Metacore pathway analysis of CTCF repressed or CTCF induced genes. (D) In siControl or siCTCF transfected MCF-7
cells, cell growth was measured when cells were stimulated with E2 (100 nM) and/or with Fulvestrant (1 M). The data are the mean of six independent
replicates ± s.d.
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Figure 7. Nuclear lamina facilitates CTCF chromatin interaction. (A) CTCF RIME was conducted in MCF-7 cells. Venn Diagram of CTCF interacting
proteins in cells stimulated with vehicle (0 h) or estrogen at 45 min or 3 h. (B) Nuclear lamina associated proteins and Lamin B were identified as CTCF
binding protein. The results include proteins that were identified in our CTCF RIME samples but not in in any of the IgG control RIME. (C) Signal
intensity of Lamin B at ER sites for P2RY2 ER loops. (D) Lamin B interaction by ChIP-PCR in cells transfected with siCTCF or siNT oligonucleotides.
ER sites 3 and 1 for P2RY2 ER loop were analyzed. (E) model showing plausible mechanism of interaction of CTCF with eRNAs to modulate the
expression of estrogen induced genes.
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DISCUSSION
Our study reveals an important, unanticipated interplay be-
tween CTCF and nuclear lamina that control the transcrip-
tion of ER target genes. Here, we show that CTCF plays
an active role moderating gene transcription induced by es-
trogen through its direct interaction with transcriptionally
active chromatin-regions. Importantly, we demonstrate that
estrogen-ER establishes contacts with chromatin and nu-
clear lamina, which might facilitate the mRNA transport of
cell cycle regulated genes to the cytoplasm and their subse-
quent translation. However, as this happens, the fraction of
CTCF associated with the nuclear lamina establishes con-
tacts with transcriptionally active chromatin domains, lim-
iting the formation of ER loops. By doing so, the expression
of estrogen-induced genes is modulated and this results in
the moderation of breast cancer cell growth.
CTCF establishes contacts to enhancer chromatin regions to
disturb ER function
Genome-wide analyses of ER chromatin-interactions have
pointed out that most of the ER binding occurs at regions
distal from ER target genes (21). More recent reports have
shown that long-range chromatin interactions are induced
by estrogen treatment and are essential for the tight reg-
ulation of ER-mediated transcription (16). Yet, the mech-
anisms contributing to modulate ER chromatin loop for-
mation and its control of transcription remained unknown.
Now, we have demonstrated that CTCF contributes to con-
trol the estrogen-induced transcription by establishing di-
rect interaction with transcriptionally active chromatin re-
gions (Figures 1–3, Additional file 2–3). Importantly, these
chromatin interactions occur simultaneously to ER binding
with the chromatin (Figures 4 and 5A). The results of this
study also demonstrate that the depletion of CTCF is able
to increase ER-chromatin interaction at the start and end
of the loop containing the P2RY2 gene locus (Figure 5C).
Therefore, CTCF impinges in the three-dimensional loop
conformation that is needed to induce the transcription of
P2RY2. Interestingly, our study has revealed that CTCF
binds to half of the ER chromatin loops, which suggests that
CTCF might function as a common negative regulator of
ER looping formation. Other factors involved in chromatin
organization, such as Cohesin, play a central role in regu-
lating long-range interactions and transcription. While Co-
hesin seems to be generally involved in transcriptional acti-
vation (3), CTCF seems to block enhancer function when
placed between enhancers and promoters. Recently, San-
born et al. (22) have proposed the existence of chromatin
domains, which are flanked by CTCF and cohesin. How-
ever, Sanborn’s study is not in disagreement with the con-
clusions of our study. We propose that ER loops hindered
by CTCF might occur within these chromatin domain de-
scribed in Sanborn’s study. In other words, ER loops might
be formed inside larger CTCF loops. Then, one might hy-
pothesize that CTCF plays different roles in the control of
transcription by: (i) maintaining the structure of chromatin
domains and (ii) regulating the formation of ER loops and
therefore modulating the expression of ER target genes.
Interestingly, considering that the average length of these
chromatin domains might be of 185 kb and that ER loops
with CTCF binding span around 68 kb (data not shown),
both events might be occurring at the same time and do not
need to exclude each other.
Previously, it has been reported that a substantial fraction
of long-range chromatin interactions between enhancers
and promoters are not impeded by the presence of CTCF
binding sites (5). Indeed, we did also observe that the ex-
pression of a subset of estrogen-induced genes is induced
by CTCF that suggests that in some instances CTCF may
also favor enhancer–promoter interactions of a subset of
estrogen-induced genes.
Other previous reports also showed a correlation between
CTCFandER regions and those regions are not strongly in-
fluenced by estrogen (15,23). Our Pearson correlation (Ad-
ditional file 2) analysis revealed that CTCF chromatin in-
teractions are stable but also demonstrate that selective
CTCF chromatin interactions might be facilitated by estro-
gen (Figures 1–3). In addition, we also plotted the CTCF
data set of that study toward that subset of ER chromatin
loop. Importantly, we also detected a substantial enrich-
ment of CTCF signal with estrogen when compared with
vehicle (data not shown).
CTCF associated with nuclear matrix buffers cell growth by
controlling estrogen induced gene transcription
Our study has also elucidated the mechanism underlying
CTCF repressive effects on ER-induced genes. Here, we
demonstrate that the fraction of CTCF associated with nu-
clear lamina, establishes contacts with enhancer chromatin
regions and TSS when ER-loops establish contacts with nu-
clear lamina (Figure 7, Additional file 7). These findings
led us to establish the hypothesis that CTCF-nuclear lamina
complex play an active role in the control of transcription
of ER target genes.
Interestingly, CTCF has been shown to physically inter-
act with RNA polymerase (Pol) II and to recruit it to spe-
cific CTCF binding sites genome wide (24). This interaction
between CTCF and RNA Pol II has been associated with
transcriptional pausing (7). Our proteomic experiments re-
veal that CTCF binds with RNA pol2-associated proteins
(Figure 7B), which is in agreement with previous publica-
tions. Together, these results suggest that CTCF binds to
chromatin with different proteins, such as lamina compo-
nents or RNA Pol2, to control estrogen induced gene tran-
scription.
In this study we show that CTCF repressed genes are
involved in cell cycle progression and that CTCF moder-
ates the cell growth of ER positive cells (Figures 4–6, Ad-
ditional file 4–6), suggesting that CTCF behaves as a tu-
mor suppressor in ER positive tumors. There are several
evidences that support this statement. First, it has been re-
ported that a subset of luminal breast cancers carry mu-
tations in the sequence of CTCF (25) and that most of
these mutations detected in breast tumors are affecting the
structure of the zinc-finger domain and therefore the bind-
ing to the DNA (26). CTCF mutations were mainly iden-
tified in Luminal A, B and HER2 enriched tumors, posi-
tive for ER. Moreover, in sporadic breast cancer, 43% of
tumors exhibited cytoplasmic CTCF expression (27). Im-
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portantly, CTCF gene is located at the 16q chromosome
arm and the loss of the chromosomal material at 16q is the
most frequent genetic event in invasive and in situ (LCIS)
lobular carcinoma of the breast (28). Finally, Ctcf hemizy-
gous knockout mice are markedly susceptible to sponta-
neous, radiation- and chemically-induced cancer in a broad
range of tissues. Ctcf± tumors are characterized by in-
creased aggressiveness, including invasion, metastatic dis-
semination and mixed epithelial/mesenchymal differentia-
tion (29). These evidences indicate that CTCF is a frequent
target that breast cancer cells mutate or inactivate in order
to prevail and outgrow normal cells. Notably, in this study,
we highlight its importance for the definition of the chro-
matin landscape of breast cancer cells andwe providemech-
anistic cues to explain how any genomic alteration impact-
ing CTCF function can affect proliferation of breast cancer
cells. Therefore, CTCF emerges as a new player in the in-
tricate network of transcription factors regulating gene ex-
pression during breast cancer progression.
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